Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma

Documenti analoghi

• Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
  di: Benteyn, Daphné, et al.
  Pubblicazione: (2013)
• Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
  di: Wilgenhof, Sofie, et al.
  Pubblicazione: (2015)
• TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
  di: De Keersmaecker, Brenda, et al.
  Pubblicazione: (2020)
• Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
  di: Wilgenhof, Sofie, et al.
  Pubblicazione: (2012)
• Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4(+) and CD8(+) T Cells in Melanoma Patients
  di: Van Nuffel, An MT, et al.
  Pubblicazione: (2012)